Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada

For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ball, Graeme, Lemieux, Christopher, Cameron, David, Seftel, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/
https://www.ncbi.nlm.nih.gov/pubmed/35323364
http://dx.doi.org/10.3390/curroncol29030164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/
https://www.ncbi.nlm.nih.gov/pubmed/35323364
http://dx.doi.org/10.3390/curroncol29030164

Ejemplares similares